Helen Kuno
Endocrinology, Diabetes & Metabolism · Midlothian, VANPI 1669464665
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 178 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,138 and has fallen 89.1% since, to $124 in 2025.
Across 178 payments — averaging $15.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$591
- AstraZeneca$308
- Amgen$279
- Lilly USA, LLC$230
- Sanofi-aventis U.S. LLC$186
- Boehringer Ingelheim$170
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,836100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 41 | $591 |
| AstraZeneca | 23 | $308 |
| Amgen(2 entities) | 11 | $279 |
| Lilly USA, LLC | 14 | $230 |
| Sanofi-aventis U.S. LLC | 10 | $186 |
| Boehringer Ingelheim | 10 | $170 |
| Abbott | 12 | $149 |
| Dexcom, Inc. | 5 | $117 |
| Xeris Pharmaceuticals, Inc. | 6 | $86 |
| Esperion Therapeutics, Inc. | 5 | $85 |
| Amneal Pharmaceuticals LLC | 6 | $79 |
| Insulet Corporation | 3 | $64 |
| Antares Pharma, Inc. | 3 | $62 |
| AbbVie | 4 | $51 |
| IBSA Pharma Inc. | 2 | $48 |
| Valeritas, Inc. | 3 | $47 |
| Merck | 3 | $37 |
| Mannkind Corporation | 2 | $28 |
| Amarin Pharma, Inc. | 2 | $27 |
| Shire North American Group Inc | 2 | $24 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Nalpropion Pharmaceuticals LLC | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Lifescan, Inc. | 1 | $15 |
| Medtronic | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Clarus Therapeutics Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Eisai Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,836 in reported general payments places this provider in the 65th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
See all endocrinology, diabetes & metabolism providers in Virginia →
Other endocrinology, diabetes & metabolism in Midlothian
- Samamtha HudsonMidlothian$372K
- Ben PhillipsMidlothian$99K
- Meredith BergerMidlothian$32K
- Christina WagnerMidlothian$8K
- Matthew LaroeMidlothian$7K
- Farhad ZangenehSterling$1.2M
- James MulindaRoanoke$788K
- Jeffrey SicatGlen Allen$657K
- Dewey BaileyRoanoke$645K
- Domenica RubinoArlington$608K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.